Michael Aitchison
The Royal Free Hospital, Royal Free London NHS Foundation Trust
Papers
2
Total Citations
42
H-Index
2
About
Michael Aitchison is a leading urological surgeon and clinical researcher whose work centers on optimizing treatment for small renal masses (SRMs) — kidney tumors ≤4 cm that are increasingly detected incidentally. His major contribution is pioneering high-level evidence in a field historically reliant on observational data. Aitchison leads the landmark NEST (Nephron Sparing Treatment) trial, a cohort-embedded randomized controlled feasibility study comparing percutaneous cryoablation (CRA) to robot-assisted partial nephrectomy (RAPN). This work directly addresses the critical challenge of surgical overtreatment for indolent SRMs, aiming to reduce health burden while preserving renal function. His 2023 feasibility trial results and 2019 protocol paper have each garnered 21 citations, establishing a foundation for future definitive RCTs in nephron-sparing surgery. Aitchison’s research is notable for its innovative trial design, overcoming historical accrual failures in SRM studies, and for its direct clinical relevance — guiding urologists and patients toward evidence-based, minimally invasive treatment decisions.
Research Focus
Key Achievements
Top Papers
- 1
- 2